Shape 21 Experience
    Shape 21 Experience
      1. Home
      2. Hemostasis and COVID-19

      siemens healthineers at aacc 2020

      Hemostasis and COVID-19

      Managing coagulation abnormalities in COVID-19 patients

      For more than 40 years, Siemens Healthineers has been recognized as a global leader in hemostasis testing. We offer the broadest range of scalable hemostasis systems for low-, mid- and high-volume laboratories. Our comprehensive portfolio of coagulation assays supports physicians in making sound diagnostic and therapeutic decisions.

      siemens healthineers at aacc 2020

      Current testing and treatment protocols

      As part of our commitment to labs and clinicians in the fight against the pandemic, we aim to keep you informed on current coagulation testing and monitoring recommendations for COVID-19 patients. Read our e-book for an overview of risk factors, recommended therapy, and testing.

      COVID-19 patients are experiencing serious—

      and sometimes fatal—clotting abnormalities

      Studies show that about 25%1—or even up to 70%2— of critically ill patients have confirmed venous thromboembolism (VTE) or pulmonary embolism (PE). Another study found that approximately 70% of COVID-19 patients who died had disseminated intravascular coagulation (DIC).3 Learn more about the facts and figures.

      INNOVANCE reagents for detection and monitoring of coagulation disorders

      Following a COVID-19 diagnosis, hemostasis testing, therapy, and monitoring play an imperative role in COVID-19 patient management. Our proven INNOVANCE® assays will help you gain efficiencies, increase operational workflow and throughput, and better manage your resources.

      siemens healthineers at aacc 2020

      INNOVANCE D-Dimer Assay

      Indicated for use in conjunction with a clinical pretest probability (PTP) assessment model to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE) in outpatients suspected of DVT or PE.


      siemens healthineers at aacc 2020

      INNOVANCE Heparin Assay

      Generates test results with easy-to-use liquid reagents and a single calibration curve for both unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH).


      siemens healthineers at aacc 2020

      INNOVANCE Antithrombin Assay

      State-of-the-art reagent for the detection of congenital or acquired antithrombin deficiencies.


      Don’t miss these events!

      Join our highlights and scientific sessions.

      1

      Klok FA, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.

      2

      Llitjos et al_High incidence of venous thromboembolic events in anticoagulated severe COVID-19. J Thromb Haemost. 2020.

      3

      Tang N, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020.

      INNOVANCE and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is a trademark of the Sysmex Corporation. All other brands and trademarks are the property of their respective owners.

      Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.